Click on one of our study types below, or scroll to view our full list of available mental health studies.  If you find one of our psychopharmacology research studies that you’re interested in, fill out our easy volunteer form to apply.

Schizophrenia | Borderline Personality DisorderMajor Depression

Disorder: Schizophrenia

Sponsor: Boehringer Ingelheim

Study: 1346-0038 This study tests whether BI 425809 together with computerized brain training improves mental functioning in patients with schizophrenia

Description: This study tests whether BI 425809 together with brain training using a computer improves mental functioning in patients with schizophrenia.  Patients will continue taking their current medications throughout the trial.  This is a 12-week trial in which patients on placebo vs BI 425809 will be compared on several neurocognitive tests as well as schizophrenic symptoms.

Demographics: Patients with schizophrenia who have stable symptoms and medications.

Ages: 18-50

Study Coordinators: Christina Ward, Kayelee Auer

Sponsor: Corcept Therapeutics

Study: CORTl 18335-876 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients with Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications

Description: This trial is being conducted to determine if Miricorilant is effective in limiting weight gain by patients who are taking antipsychotic medications.  It is a 12-week double-blind trial that compares the active medication with placebo.

Demographics: Males and females who recently started olanzapine, risperidone, or quetiapine and have since shown an increase in body weight.

Ages: 18-65

Study Coordinators: Christina Ward, Kayelee Auer

Disorder: Borderline Personality Disorder

Sponsor: Otsuka Pharmaceutical Development & Commercialization

Study: 331-201-00242 A Trial of Brexipiprazole in the Treatment of Borderline Personality Disorder.

Description: This trial is being conducted to determine if Rexulti (brexipiprazole) is effective for patients who suffer from Borderline Personality Disorder.  It is a 12-week double-blind trial that compares the active medication with placebo.  Subjects who respond well and complete the study may be eligible for another long-term trial in which all patients will receive Rexulti.

Demographics: Males and females with a primary diagnosis of Borderline Personality Disorder

Ages: 18-65

Study Coordinator: Christina Ward, Kayelee Auer

Disorder: Major Depression

Sponsor: Otsuka Pharmaceutical Development & Commercialization

Study: 331-201-00079 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder.

Description: This study is being conducted to determine if Rexulti (brexipiprazole) is effective for patients who suffer from Depression and who have only partly responded to an antidepressant.  Participants will have Rexulti added to their current antidepressant.  Those who respond successfully to the Rexulti will subsequently be randomized to placebo or a continuation of the Resulti.

Demographics: Males and females with a primary diagnosis of major depression.

Ages: 18-65

Study Coordinator: Christina Ward, Kayelee Auer, Camille Pommerville

Resources

ClinicalTrials.gov provides easy and free access to information on clinical studies around the world.  The trials we participate in are registered with this website.  This website also includes a glossary of terms related to clinical studies, clinical trials and medical research.